{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:34:59Z","timestamp":1785544499462,"version":"3.56.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"31","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Blood eosinophil (EOS) count has emerged as a potential biomarker associated with inhaled corticosteroid (ICS) responsiveness in chronic obstructive pulmonary disease (COPD). However, the relationship between EOS counts and clinical outcomes during ICS treatment in stable-phase COPD remains unclear. This study aimed to evaluate the association between baseline EOS counts and changes in lung function, symptom burden, and exacerbation frequency during ICS\/long-acting \u03b2\n                      <jats:sub>2<\/jats:sub>\n                      -agonist (LABA) treatment. A retrospective cohort study included 200 stable-phase COPD patients treated with ICS\/LABA combinations for 12 months. Participants were stratified into low (&lt;150 cells\/\u03bcL), medium (150\u2013300 cells\/\u03bcL), and high (&gt;300 cells\/\u03bcL) EOS groups. Outcomes included changes in forced expiratory volume in 1 second (FEV1%pred), COPD Assessment Test scores, 6-minute walk distance, and annualized exacerbation rates. Inflammatory markers (interleukin-5 [IL-5], eosinophil cationic protein) were analyzed. Baseline EOS counts were positively correlated with IL-5 and eosinophil cationic protein. After 12 months, higher baseline EOS counts were associated with greater changes in FEV1%pred and 6-minute walk distance. The reduction in exacerbation rates was 51.9% in the high EOS group versus 22.3% in the low EOS group. Receiver operating characteristic analysis identified a baseline EOS cutoff of 285 cells\/\u03bcL for predicting FEV1%pred improvement \u22655%. Higher baseline EOS counts are associated with greater improvements in clinical outcomes during ICS\/LABA therapy in stable COPD, although the absence of a non-ICS comparator precludes causal inference. These findings support further investigation of EOS-guided treatment strategies in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049634","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:28:36Z","timestamp":1785533316000},"page":"e49634","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["The association between blood eosinophil count and clinical outcomes during inhaled corticosteroid\/long-acting \u03b22-agonist treatment in stable-phase chronic obstructive pulmonary disease: A retrospective cohort analysis"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8854-258X","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"first","affiliation":[{"name":"Respiratory Department, Shaoxing City Keqiao District Hospital of Traditional Chinese Medicine, Shaoxing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghai","family":"Chen","sequence":"additional","affiliation":[{"name":"Respiratory Department, Shaoxing City Keqiao District Hospital of Traditional Chinese Medicine, Shaoxing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260731","doi-asserted-by":"crossref","first-page":"925132","DOI":"10.3389\/fphys.2022.925132","article-title":"Global, regional, and national burden of chronic obstructive pulmonary disease from 1990 to 2019.","volume":"13","author":"Wang","year":"2022","journal-title":"Front Physiol"},{"key":"R2-20260731","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/respcare.12264","article-title":"Effect of smoking on mortality in individuals with COPD in the United States.","volume":"70","author":"Adebile","year":"2025","journal-title":"Respir Care"},{"key":"R3-20260731","doi-asserted-by":"crossref","first-page":"300060520919567","DOI":"10.1177\/0300060520919567","article-title":"Effects of comprehensive and intensive pulmonary rehabilitation and nutritional support on quality of life and functional status in patients with chronic obstructive pulmonary disease.","volume":"48","author":"Korkmaz","year":"2020","journal-title":"J Int Med Res"},{"key":"R4-20260731","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.202310-872ST","article-title":"Challenges and opportunities for commercializing technologies in the pulmonary arena: an official American Thoracic Society report.","volume":"21","author":"Vukmirovic","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"R5-20260731","doi-asserted-by":"crossref","first-page":"240099","DOI":"10.1183\/20734735.0099-2024","article-title":"Diagnosis and management of comorbid disease in COPD.","volume":"21","author":"Cronin","year":"2025","journal-title":"Breathe (Sheff)"},{"key":"R6-20260731","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2174\/0113862073349683241226100233","article-title":"Effects of inhaled corticosteroids\/long-acting beta-agonists (ICS\/LABA) on airway microbial diversity and IL-8\/IL-10 cytokine levels in stable COPD.","volume":"29","author":"Fang","year":"2026","journal-title":"Comb Chem High Throughput Screen"},{"key":"R7-20260731","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1159\/000544938","article-title":"Inhaled Corticosteroid-long-acting beta-2 agonist fixed-dose combinations: preferred controller in 6- to 11-year-olds with persistent asthma.","volume":"186","author":"Koken","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"R8-20260731","doi-asserted-by":"crossref","first-page":"2000351","DOI":"10.1183\/13993003.00351-2020","article-title":"Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline.","volume":"55","author":"Chalmers","year":"2020","journal-title":"Eur Respir J"},{"key":"R9-20260731","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.jaci.2025.02.037","article-title":"Plasma pharmacometabolomics of inhaled corticosteroid-related adrenal suppression in asthma.","volume":"155","author":"Tran","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"R10-20260731","doi-asserted-by":"crossref","first-page":"2001251","DOI":"10.1183\/13993003.01251-2020","article-title":"Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study.","volume":"57","author":"Chalitsios","year":"2021","journal-title":"Eur Respir J"},{"key":"R11-20260731","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.chest.2024.06.3790","article-title":"Rethinking blood eosinophils for assessing inhaled corticosteroids response in COPD: a post hoc analysis from the FLAME trial.","volume":"166","author":"Mathioudakis","year":"2024","journal-title":"Chest"},{"key":"R12-20260731","doi-asserted-by":"crossref","first-page":"1902119","DOI":"10.1183\/13993003.02119-2019","article-title":"Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD.","volume":"55","author":"Mathioudakis","year":"2020","journal-title":"Eur Respir J"},{"key":"R13-20260731","doi-asserted-by":"crossref","first-page":"14799731241296847","DOI":"10.1177\/14799731241296847","article-title":"Eosinopenia in bronchiectasis: a novel biomarker for morbidity and mortality.","volume":"22","author":"Izhakian","year":"2025","journal-title":"Chron Respir Dis"},{"key":"R14-20260731","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","article-title":"Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.","volume":"154","author":"Bacharier","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"R15-20260731","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00228-019-02667-4","article-title":"Discontinuation of therapy among COPD patients who experience an improvement in exacerbation status.","volume":"75","author":"Reilev","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20260731","doi-asserted-by":"crossref","first-page":"847","DOI":"10.21037\/jtd-22-1769","article-title":"A comparison of GOLD 2019 and 2023 recommendations to contemporaneous real-world inhaler treatment patterns for chronic obstructive pulmonary disease management in Singapore.","volume":"16","author":"Alsuwaigh","year":"2024","journal-title":"J Thorac Dis"},{"key":"R17-20260731","doi-asserted-by":"crossref","first-page":"2300484","DOI":"10.1183\/13993003.00484-2023","article-title":"Implication of the global initiative for chronic obstructive lung disease 2023 report for resource-limited settings: tracing the G in the GOLD.","volume":"61","author":"Kirenga","year":"2023","journal-title":"Eur Respir J"},{"key":"R18-20260731","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1164\/rccm.202407-1287RL","article-title":"Blood eosinophil count stability in chronic obstructive pulmonary disease and the eosinophilic exacerbator phenotype.","volume":"211","author":"Baraldi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"R19-20260731","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/17476348.2021.2011219","article-title":"Blood eosinophils in COPD: friend or foe?","volume":"16","author":"Papaporfyriou","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"R20-20260731","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.mucimm.2024.03.005","article-title":"IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.","volume":"17","author":"Luo","year":"2024","journal-title":"Mucosal Immunol"},{"key":"R21-20260731","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2147\/COPD.S155306","article-title":"Targeting IL-5 in COPD.","volume":"14","author":"Narendra","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R22-20260731","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12890-021-01443-4","article-title":"The association between eosinophilic exacerbation and eosinophilic levels in stable COPD.","volume":"21","author":"Kang","year":"2021","journal-title":"BMC Pulm Med"},{"key":"R23-20260731","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1080\/02770903.2022.2136526","article-title":"Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma.","volume":"60","author":"Menigoz","year":"2023","journal-title":"J Asthma"},{"key":"R24-20260731","first-page":"1884","article-title":"Eosinophil cationic protein variation in patients with asthma and CRSwNP treated with dupilumab.","volume":"13","author":"Ledda","year":"2023","journal-title":"Life (Basel)"},{"key":"R25-20260731","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s11596-019-2074-7","article-title":"Application of inflammatory markers in induced sputum in stable chronic obstructive pulmonary disease patients with positive bronchodilation tests.","volume":"39","author":"Guo","year":"2019","journal-title":"Curr Med Sci"},{"key":"R26-20260731","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2147\/COPD.S347588","article-title":"Efficacy of ICS versus non-ICS combination therapy in COPD: a meta-analysis of randomised controlled trials.","volume":"17","author":"Ding","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R27-20260731","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2147\/COPD.S258353","article-title":"The association between eosinophil variability patterns and the efficacy of inhaled corticosteroids in stable COPD patients.","volume":"15","author":"Yoon","year":"2020","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R28-20260731","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/thoraxjnl-2020-215167","article-title":"Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait.","volume":"76","author":"David","year":"2021","journal-title":"Thorax"},{"key":"R29-20260731","doi-asserted-by":"crossref","first-page":"14724","DOI":"10.1038\/s41598-023-41726-w","article-title":"Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions.","volume":"13","author":"Nishii","year":"2023","journal-title":"Sci Rep"},{"key":"R30-20260731","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12890-024-03027-4","article-title":"Clinical significance and potential pathogenesis of VCAN in adult non-cystic fibrosis bronchiectasis: a retrospective study.","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"R31-20260731","doi-asserted-by":"crossref","first-page":"1411408","DOI":"10.3389\/fimmu.2024.1411408","article-title":"Altered levels of IFN-\u03b3, IL-4, and IL-5 depend on the TLR4 rs4986790 genotype in COPD smokers but not those exposed to biomass-burning smoke.","volume":"15","author":"Gutierrez-Romero","year":"2024","journal-title":"Front Immunol"},{"key":"R32-20260731","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/COPD.S495073","article-title":"The mediation of circulating inflammatory proteins in the causal pathway from immune cells to COPD.","volume":"20","author":"Yan","year":"2025","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"R33-20260731","doi-asserted-by":"crossref","first-page":"e70229","DOI":"10.1111\/jcmm.70229","article-title":"Peribronchial inflammatory cell assessment in COPD lung tissues.","volume":"28","author":"Devilliers","year":"2024","journal-title":"J Cell Mol Med"},{"key":"R34-20260731","doi-asserted-by":"crossref","first-page":"RP85875","DOI":"10.7554\/eLife.85875.3","article-title":"Short-range interactions between fibrocytes and CD8+ T cells in COPD bronchial inflammatory response.","volume":"12","author":"Eyraud","year":"2023","journal-title":"Elife"},{"key":"R35-20260731","doi-asserted-by":"crossref","first-page":"2000515","DOI":"10.1183\/13993003.00515-2020","article-title":"Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study.","volume":"57","author":"Janson","year":"2020","journal-title":"Eur Respir J"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049634","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T21:28:41Z","timestamp":1785533321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":35,"journal-issue":{"issue":"31","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049634","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2025-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}